Skip to main content
. 2021 Jul 12;12:710044. doi: 10.3389/fimmu.2021.710044

Figure 1.

Figure 1

Anti-HIV-1 broadly neutralizing antibodies in clinical trials and their targets on the HIV-1 envelope.